|
1
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mahaley MS Jr, Mettlin C, Natarajan N,
Laws ER Jr and Peace BB: National survey of patterns of care for
brain-tumor patients. J Neurosurg. 71:826–836. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Athanassiou H, Synodinou M, Maragoudakis
E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G,
Beroukas K and Karageorgis P: Randomized phase II study of
temozolomide and radiotherapy compared with radiotherapy alone in
newly diagnosed glioblastoma multiforme. J Clin Oncol.
23:2372–2377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnson DR and O'Neill BP: Glioblastoma
survival in the United States before and during the temozolomide
era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Dietrich PY, Ostermann Kraljevic
S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G,
Miralbell R, et al: Promising survival for patients with newly
diagnosed glioblastoma multiforme treated with concomitant
radiation plus temozolomide followed by adjuvant temozolomide. J
Clin Oncol. 20:1375–1382. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mukthavaram R, Ouyang X, Saklecha R, Jiang
P, Nomura N, Pingle SC, Guo F, Makale M and Kesari S: Effect of the
JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
J Transl Med. 13:2692015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Atkinson GP, Nozell SE and Benveniste ET:
NF-kappaB and STAT3 signaling in glioma: Targets for future
therapies. Expert Rev Neurother. 10:575–586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers. 6:708–722. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song Y, Kong L, Sun B, Gao L, Chu P, Ahsan
A, Qaed E, Lin Y, Peng J, Ma X, et al: Induction of autophagy by an
oleanolic acid derivative, SZC017, promotes ROS-dependent apoptosis
through Akt and JAK2/STAT3 signaling pathway in human lung cancer
cells. Cell Biol Int. 41:1367–1378. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng Q, Han L, Dong Y, Tian J, Huang W,
Liu Z, Jia X, Jiang T, Zhang J, Li X, et al: JAK2/STAT3 targeted
therapy suppresses tumor invasion via disruption of the
EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in
EGFRvIII-expressing glioblastoma. Neurooncol. 16:1229–1243.
2014.
|
|
13
|
Stechishin OD, Luchman HA, Ruan Y, Blough
MD, Nguyen SA, Kelly JJ, Cairncross JG and Weiss S: On-target
JAK2/STAT3 inhibition slows disease progression in orthotopic
xenografts of human glioblastoma brain tumor stem cells. Neuro
Oncol. 15:198–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Höfener M, Pachl F, Kuster B and Sewald N:
Inhibitor-based affinity probes for the investigation of JAK
signaling pathways. Proteomics. 15:3066–3074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iurlo A and Cattaneo D: Treatment of
myelofibrosis: Old and new strategies. Clin Med Insights Blood
Disord. 10:1179545×176952332017. View Article : Google Scholar
|
|
16
|
Pardanani A, Abdelrahman RA, Finke C,
Lasho TT, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA,
Ketterling RP, et al: Genetic determinants of response and survival
in momelotinib-treated patients with myelofibrosis. Leukemia.
29:741–744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang S, Imamura Y, Jenkins RW, Cañadas I,
Kitajima S, Aref A, Brannon A, Oki E, Castoreno A, Zhu Z, et al:
Autophagy inhibition dysregulates TBK1 signaling and promotes
pancreatic inflammation. Cancer Immunol Res. 4:520–530. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan E, Luwor R, Burns C, Kannourakis G,
Findlay JK and Ahmed N: Momelotinib decreased cancer stem cell
associated tumor burden and prolonged disease-free remission period
in a mouse model of human ovarian cancer. Oncotarget.
9:16599–16618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lue HW, Cole B, Rao SA, Podolak J, Van
Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, et al: Src
and STAT3 inhibitors synergize to promote tumor inhibition in renal
cell carcinoma. Oncotarget. 6:44675–44687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu Y, Dong XZ, Liu X, Liu P and Chen YB:
Enhanced antitumor activity of cetuximab in combination with the
Jak inhibitor CYT387 against non-small-cell lung cancer with
various genotypes. Mol Pharm. 13:689–697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Cai J, Zhao S, Yao K, Sun Y, Li Y,
Chen L, Li R, Zhai X, Zhang J, et al: GANT61, a GLI inhibitor,
sensitizes glioma cells to the temozolomide treatment. J Exp Clin
Cancer Res. 35:1842016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu
WW, Wang K, Gao L, Qi ST and Lu YT: miR-519a enhances
chemosensitivity and promotes autophagy in glioblastoma by
targeting STAT3/Bcl2 signaling pathway. J Hematol Oncol. 11:702018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q,
Liu J, Liu T and Zhang Q: The PI3K inhibitor GDC-0941 enhances
radiosensitization and reduces chemoresistance to temozolomide in
GBM cell lines. Neuroscience. 346:298–308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu J, Liu ZG, Liu XM, Chen FR, Shi HL,
Pangjesse CS, Ng HK and Chen ZP: Glioblastoma stem cells resistant
to temozolomide-induced autophagy. Chin Med J. 122:1255–1259.
2009.PubMed/NCBI
|
|
25
|
Bak DH, Kang SH, Choi DR, Gil MN, Yu KS,
Jeong JH, Lee NS, Lee JH, Jeong YG, Kim DK, et al: Autophagy
enhancement contributes to the synergistic effect of vitamin D in
temozolomide-based glioblastoma chemotherapy. Exp Ther Med.
11:2153–2162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Natsumeda M, Aoki H, Miyahara H, Yajima N,
Uzuka T, Toyoshima Y, Kakita A, Takahashi H and Fujii Y: Induction
of autophagy in temozolomide treated malignant gliomas.
Neuropathology. 31:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin CJ, Lee CC, Shih YL, Lin CH, Wang SH,
Chen TH and Shih CM: Inhibition of mitochondria- and endoplasmic
reticulum stress-mediated autophagy augments temozolomide-induced
apoptosis in glioma cells. PLoS One. 7:e387062012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou Y, Wang Q, Li B, Xie B and Wang W:
Temozolomide induces autophagy via ATMAMPKULK1 pathways in glioma.
Mol Med Rep. 10:411–416. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lue HW, Podolak J, Kolahi K, Cheng L, Rao
S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, et al:
Metabolic reprogramming ensures cancer cell survival despite
oncogenic signaling blockade. Genes Dev. 31:2067–2084. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tyner JW, Bumm TG, Deininger J, Wood L,
Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E and
Deininger MW: CYT387, a novel JAK2 inhibitor, induces hematologic
responses and normalizes inflammatory cytokines in murine
myeloproliferative neoplasms. Blood. 115:5232–5240. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cotter TG: Apoptosis and cancer: The
genesis of a research field. Nat Rev Cancer. 9:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu J, Feng X, Zhang B, Li J, Xu X, Liu J,
Wang X, Wang J and Tong X: Blocking the bFGF/STAT3 interaction
through specific signaling pathways induces apoptosis in
glioblastoma cells. J Neurooncol. 120:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sai K, Wang S, Balasubramaniyan V, Conrad
C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, et
al: Induction of cell-cycle arrest and apoptosis in glioblastoma
stem-like cells by WP1193, a novel small molecule inhibitor of the
JAK2/STAT3 pathway. J Neurooncol. 107:487–501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abubaker K, Luwor RB, Zhu H, McNally O,
Quinn MA, Burns CJ, Thompson EW, Findlay JK and Ahmed N: Inhibition
of the JAK2/STAT3 pathway in ovarian cancer results in the loss of
cancer stem cell-like characteristics and a reduced tumor burden.
BMC Cancer. 14:3172014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Monaghan KA, Khong T, Burns CJ and Spencer
A: The novel JAK inhibitor CYT387 suppresses multiple signalling
pathways, prevents proliferation and induces apoptosis in
phenotypically diverse myeloma cells. Leukemia. 25:1891–1899. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Beaujouin M, Baghdiguian S, Glondu-Lassis
M, Berchem G and Liaudet-Coopman E: Overexpression of both
catalytically active and -inactive cathepsin D by cancer cells
enhances apoptosis-dependent chemo-sensitivity. Oncogene.
25:1967–1973. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun T, Jia Y and Xiao D: Interference of
STAT 5b expression enhances the chemo-sensitivity of gastric cancer
cells to gefitinib by promoting mitochondrial pathway-mediated cell
apoptosis. Oncol Rep. 34:227–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Y, Li R, Pan M, Shi Z, Yan W, Liu N,
You Y, Zhang J and Wang X: MiR-181b modulates chemosensitivity of
glioblastoma multiforme cells to temozolomide by targeting the
epidermal growth factor receptor. J Neurooncol. 133:477–485. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim MS, Lee WS, Jeong J, Kim SJ and Jin W:
Induction of metastatic potential by TrkB via activation of
IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget.
6:40158–40171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun KX, Xia HW and Xia RL: Anticancer
effect of salidroside on colon cancer through inhibiting JAK2/STAT3
signaling pathway. Int J Clin Exp Pathol. 8:615–621.
2015.PubMed/NCBI
|
|
41
|
Abubaker K, Luwor RB, Escalona R, McNally
O, Quinn MA, Thompson EW, Findlay JK and Ahmed N: Targeted
disruption of the JAK2/STAT3 pathway in combination with systemic
administration of paclitaxel inhibits the priming of ovarian cancer
stem cells leading to a reduced tumor burden. Front Oncol.
4:752014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu JR, Wu WJ, Liu SX, Zuo LF, Wang Y,
Yang JZ and Nan YM: Nimesulide inhibits the growth of human
esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.
Pathol Res Pract. 211:426–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Park KR, Yun HM, Quang TH, Oh H, Lee DS,
Auh QS and Kim EC: 4-Methoxydalbergione suppresses growth and
induces apoptosis in human osteosarcoma cells in vitro and in vivo
xenograft model through down-regulation of the JAK2/STAT3 pathway.
Oncotarget. 7:6960–6971. 2016.PubMed/NCBI
|
|
44
|
Walker SR, Xiang M and Frank DA: Distinct
roles of STAT3 and STAT5 in the pathogenesis and targeted therapy
of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu C, Zhu Y, Lou W, Cui Y, Evans CP and
Gao AC: Inhibition of constitutively active Stat3 reverses
enzalutamide resistance in LNCaP derivative prostate cancer cells.
Prostate. 74:201–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
